THE ROLE OF STATINS IN DEEP VEIN THROMBOSIS
|
|
- Mark Horn
- 6 years ago
- Views:
Transcription
1 Rev. Med. Chir. Soc. Med. Nat., Iaşi 2012 vol. 116, no. 3 INTERNAL MEDICINE - PEDIATRICS UPDATES THE ROLE OF STATINS IN DEEP VEIN THROMBOSIS Maria-Magdalena Leon 1,4, Elena Cojocaru 2, Roxana Cobzaru 3, Amalia Didii 1, F. Mitu 1,4 University of Medicine and Pharmacy Grigore T. Popa - Iaşi School of Medicine 1. Discipline of Medical Semiology 2. Discipline of Histology 3. Discipline of Parasitology 4.Clinical Hospital of Recovery, Iaşi THE ROLE OF STATINS IN DEEP VEIN THROMBOSIS (Abstract): Deep vein thrombosis (DVT) represents the formation of a blood clot in one of the deep veins of our body, predominantly occurring in the legs. According to international guidelines, the goal of the treatment in deep vein thrombosis is to prevent the progression and the recurrences of thrombotic process. The aim of this article is to explain the pathogenetic mechanism of deep vein thrombosis and the benefits of statins in such a disease. The vasoprotective effects of statins are related to their anti-thrombotic and anti-inflammatory properties. The administration of statins is associated with a lower incidence of venous thromboembolism (VTE) in the general population. It also helps in reducing the frequency of recurrences, being prescribed after an optimal 6 to12 month anticoagulation. The study of these properties creates new opportunities for the use of statins in the prevention of post-thrombotic syndrome and recurrent venous thromboembolism (VTE). Key words: STATINS, VENOUS THROMBOSIS, THROMBOEMBOLISM. About 1 in a 1000 adults develops annually a Deep Vein Thrombosis (DVT). The incidence increases from 0.01% in young adults to 1% in people over 60. More than half of these events involve deep vein thrombosis in the inferior vena cava basin. In 25% of untreated cases, the thrombi extend towards proximal veins. Consequently, in the case of proximal DVT the risk of asymptomatic or symptomatic pulmonary thrombo-embolism increases to 5% and that is more likely to occur if the emboli are caused by proximal thrombi. In order to decrease the risk of fatal pulmonary emboli, the early diagnosis and prompt treatment of DVT are essential. DVT pathogenesis mentions three broad categories of factors also known as Virchow s triad: endothelial injury, venous stasis and hypercoagulability. The vessel wall injury interferes with the coagulation inhibition function and prevents the local fibrinolytic process of the endothelium. Venous stasis, caused by patient immobilization or vein obstruction blocks the clearance and dilution of activated coagulation factors and finally the congenital or acquired thrombophilia, leading to hypercoagulation. The venous thromboembolism pathogenesis is multifactorial, often resulting from a combination of several risk factors. The most common risk factors for secondary venous thrombosis include cancer, 817
2 Maria-Magdalena Leon et al surgery, immobilization for long periods of time, fractures, paralysis, pregnancy, birth and use of estrogens or of selective estrogen receptor modulators. Still, for approximately 30% of the patients the cause of DVT occurrence remain inexplicable, the same as in the case of spontaneous or idiopathic thrombosis. THE CORRELATION BETWEEN DEEP VEIN THROMBOSIS AND ATHEROSCLEROSIS PROCESS The existence of an association between atherosclerosis and idiopathic venous thrombosis was demonstrated for the first time in 2003 by Professor Prandoni and his research group. In a clinical case-control study about half of the patients diagnosed with idiopathic acute venous thrombosis developed signs of asymptomatic atherosclerosis (at least one carotid atherosclerotic plague, estimated by scanning the carotid arteries) (1). The essence of this association is still unknown: could venous thrombosis be induced by atherosclerosis or do the two conditions have a parallel development, in the presence of common risk factors? Certain factors correlated to the development of both pathologies have been identified: old age, obesity, diabetes mellitus, the metabolic syndrome (2). On the one hand the prothrombotic state in atherosclerosis can favor venous thrombotic events. In the case of atherosclerosis (ASVD) the evaluated elements are: the plaque aggregation activation, the blood coagulation activation and the increase of fibrogenesis. All these elements can lead to thrombotic complications both at the arterial level and in the venous system. On the other hand, both clinical conditions can be simultaneously triggered by certain biological stimuli, responsible for the activation of coagulation and swelling in the vascular system. Thus, the excess of fibrinogen, von Willebrand factor antigen, plasminogen tissue activator, D-dimers, coagulation factor VII, C-reactive protein (CRP), tumor necrosis factor- α (TNF-α) and interleukin, that circulate in the blood, cause a procoagulant and pro-inflammatory state both in the venous and the arterial system (3). We cannot exclude the probability that both hypothesis are true, representing thus two pathophysiologic scenarios for the development of venous thrombosis. These hypotheses are confirmed by vast authentic evidence, resulted from important clinical studies. The Cardiovascular Health Study (2009) proved that asymptomatic atherosclerosis represents a risk factor for VTE (venous thromboembolism) (4), while Atherosclerosis Risk in Communities Study (ARIC) showed that that the anti-plaque treatment and/or other antithrombotic treatments plays an important role in the prevention of venous thromboembolism dysfunctions in patients with clinically manifest atherosclerosis (5). Another study assessed the relapse rates for DVT, postthrombotic damage severity and mortality 10 years after the first VTE episode, in patients previously included in the Duration of Anticoagulation (DURAC) study. After ten years the mortality rate due to acute myocardial infarction (AMI) or fatal ictus cerebri was significantly higher (approximately 28%) in patients with spontaneous VTE, if compared with patients with secondary VTE and with the general population (6). Other randomized control trials (P. Becattini; P. Prandoni; N. Bova) demonstrate a higher incidence of symptomatic atherosclerosis (ischemic cardiomyopathy, acute myocardial infarction, cerebral vascular accident, atherosclerosis of the peripheral arteries, ischemic cardiac failure, sudden death) in patients with idio- 818
3 The role of statins in deep vein thrombosis pathic venous thrombosis if compared with patients with secondary VTE and with the general population. THE ROLE OF STATINS IN PRIMARY AND SECONDARY PREVENTION OF VTE (VENOUS THROMBOEMBOLISM) The objectives of DVT treatment, according to international guidelines, consist in the prevention of the thrombotic process progression as well as the prevention of relapses. Treatment is initiated with unfractionated heparin or low molecular weight heparin, followed by an indirect anticoagulant. The administration of direct anticoagulants will be ceased within 7-10 days while indirect anticoagulants will be administered for at least another six month, if there are no contraindications. The risk of hemorrhage occurrence represents the main criteria in the limitation of oral anticoagulant treatment duration. In most patients, the benefits of long-term prophylactic treatment of recurrent VTE can be compromised by an increased risk of bleeding, especially after 12 months of continuous administration. This fact has consequently demanded the research of alternative strategies for the secondary prevention of VTE, which have recently led to discussions about HMG-CoA reductase inhibitors (7). HMG-CoA reductase inhibitors represent one of the most commonly used groups of drugs. The special attention they are granted is justified not only by their high efficiency as hypolipidemic agents. Numerous experimental in vitro, in vivo and clinical studies have confirmed in the past years several benefic effects resulted through mechanisms that have no connection with the changes in lipid metabolism and are commonly named pleiotropic effects. The vasoprotective effect of statins is ensured by these properties, the anti-thrombotic and anti-inflammatory activity being the most important. These characteristics may lead to new perspectives regarding the post-thrombotic syndrome and VTE recurrences prevention. The discovery of connections between atherosclerosis and venous thrombosis lead to the initiation of clinical and experimental studies meant to estimate the role of statins in diminishing the VTE risk. A randomized, placebo-controlled, multicenter trial, Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), included 17,800 practically healthy subjects that received 20 mg of rosuvastatinum or placebo, its main purpose being the study of statin efficiency in the decrease of major cardiovascular events rate. The assessment of pulmonary embolism or VTE primary episodes occurrence constituted one of the secondary purposes of the trial (8). After an average surveillance period of 1.9 years (up to a maximum of 5 years) it was concluded that rosuvastatinum administration reduces the symptomatic VTE risk with 43% for the practically healthy subjects participating in the study, when compared to the administration of placebo, no matter if the episode was idiopathic or was caused by a well-known factor. Specialized literature (9) mentions a series of clinical trials that explore the alternative strategy hypothesis in the VTE prevention and provide scientific evidence of the influence of statins on VTE risk. The multicenter, observational, prospective randomized controlled clinical trial, Heart and Estrogen/Progestin Replacement Study, that included 2,763 female subjects provided data that proved a significant decrease of 50% of VTE risk in patients receiving statins. Statins determined a decrease of 22% of the relative risk of DVT 819
4 Maria-Magdalena Leon et al occurrence in patients over 65, in an observational retrospective trial that included a total of 125,000 patients with no history of atherosclerosis, venous thrombosis or cancer (10). Certain authors of case-control clinical trials mention a venous thrombosis risk decrease with approximately 26%-58% following statins therapy (11). In the population-based case-control study (MEGA study) that assessed 10,500 subjects, including 4,500 patients with primary episode of venous thrombosis in the lower limbs or pulmonary embolism, the use of statins, regardless of the active substance or the duration of the treatment, was associated with a significant 55% decrease of primary and recurrent DVT, proving to have a better effect in combination with the main treatment (13). An estimation of the venous thrombotic risk (by means of vascular Doppler) in 2,427 post-menopausal female patients aged between 30 and 89, of which 465 had a first episode of venous thrombosis, showed a significantly lower risk for the subjects who received statins (12). It was at the same time noticed that the risk rate was influenced by simvastatin, regardless of the dose, but remained unchanged in the case of pravastatin administration, probably due to differences in action at the level of coagulation activation internal mechanisms, blocked by lipophilic simvastatin and uninfluenced by hydrophilic pravastatin (13). Another such study assessed 5,824 VTE patients and a control group consisting of 58,000 subjects without a history of venous thrombosis. The outcomes lead to two important conclusions: patients with a history of cardiovascular events are exposed to a certainly higher VTE risk, especially within the first 3 month following an acute myocardial infarction or stroke; constant administration of statins is associated with a lower relative risk of VTE (approximately 26%) (14). The outcomes of a retrospective study that assessed 593 patients with myocardial infarction or ischemic cerebrovascular accident (CVA) showed that statins can be efficient for VTE prevention in atherosclerosis patients, the DVT risk being three times higher in patients who do not receive statin therapy (15). The effect depends on the dosage, being more significant in case of high doses (50% lower risk if compared with the standard 20 mg statin doses). The use of statins in the case of patients with solid tumors (colon, pancreas, breast, ovarian, renal and cerebral cancer) was associated with a relatively low probability of VTE occurrence (8% as opposed to 21% in the group without statins), including VTE and pulmonary embolism. Regression analysis provided an identical result, regardless of other factors involved, such as smoking habits, the presence of metastases, chemotherapy administration, immobilization, aspirin administration (16). In that particular context, there were some attempts to compare the effect of statins to the effect of fibrates, in a randomized control trial assessing 1,354 patients hospitalized for idiopathic venous thrombosis (17). The use of statins resulted in a significantly lower risk of recurrent VTE episodes, while fibrate administration was associated with a higher risk (0.53 vs. 1.88) (18). In another study the MEGA study other groups of hypolipemiants (non-statins) caused an increase of 22% in primary or recurrent venous thrombosis risk, compared to patients who did not received hypolipemiant drugs (19). In the above mentioned observational case-control study the female patients were administered statins, fibrates, bile acid sequestrants or niacin; a lower risk of venous thrombosis was signaled only in the group that received statins (20). 820
5 The role of statins in deep vein thrombosis The specialized literature does not produce any evidence regarding VTE aggravation or risk increase due to statins therapy. The benefic action of HMG-CoA reductase inhibitors, in the venous thrombosis pathology, is ensured by the anti-plaquetary, anticoagulant, profibrynolitic, anti-inflammatory, anti-cytokine, anti-oxidant and hypolipemiant effects that ensure all of them, the proper functioning of the vascular endothelium and finally contribute to maintaining an optimal balance between pro-thrombotic and fibrinolytic mechanisms. Manifestations of anti-thrombotic effects of statins consist in the inhibition of plaquetary aggregation, a decrease in thrombin production, the blockage of pro-thrombin activation, of the factor V and factor XVIII, the inhibition of the tissue factor with an important part in the maintenance of extrinsic coagulation cascade, the decrease of D-dimers seric level (marker of the prothrombotic state and independent risk factor for VTE recurrences), the stimulation of fibrinolytic activity through the intensification of tissue plasminogen activator (tpa) and the diminishing of plasminogen activator inhibator-1 (PAI- 1) (21). Since inflammation is known to be one of the lesion mechanisms of the vascular wall and consequently an important factor in the destabilization of coagulation-fibrinolysis processes, we cannot neglect the role of the anti-inflammatory pleiotropic effect of statins in preventing recurrent primary venous thrombosis and the development of the post-thrombotic syndrome. Statins reduce the level of inflammation markers: C- reactive protein (in the CARE, PRINCE, AFCAPS/TexCAPS studies), tumoral necrosis factor-α, -1β and -2 interleukin, fibrinogen, CD40L ligand. There exists an association between the high risk of VTE, the increase of plasmatic values of triglycerides (over 1.05 mmol/l) and the decrease of HDL cholesterol (under 1.79 mmol/1) (22). In this context, statins are benefic due to their wellknown effect on the serum lipid spectrum. CONCLUSIONS VTE is associated with high morbidity and mortality. The optimal remedy for the prevention and treatment of VTE should combine the advantages of efficiency, minimal bleeding risk and ease of administration. Statins seem to meet the last two criteria, yet their efficiency has not yet been fully demonstrated. They cannot be suggested as alternative anti-thrombotic remedies instead of oral anti-coagulants in the treatment of acute of sub-acute venous thrombosis. Yet, clinical studies demonstrate that the use of statins is rational as far as VTE prophylaxis is concerned, long-term secondary prophylaxis included. Statin therapy is associated with a decrease of VTE incidence in the general population as well as with a decrease of the incidence of recurrences, when administered after the recommended 6-12 month anticoagulant treatment. Still, more studies are needed in order to prove the efficiency of this drug for such a condition and create the opportunity to extend the indications for this group of drugs for certain population categories. REFERENCES 1. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl Med J 2003; 348 (15): Lowe GD. Common risk factors for both arterial and venous thrombosis. Br J Haematol 2008; 140 (5):
6 Maria-Magdalena Leon et al 3. Prandoni P. Venous thromboembolism and atherosclerosis: is there a link? J Thromb Haemost 2007; 5 (Suppl. 1): van der Hagen PB, Folsom AR, Jenny NS, Heckbert SR, O'Meara ES, Reich LM, et al. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006; 4 (9): Broder A, Tobin JN, Putterman C. High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. J Clin Pathol 2012; 65(6): Reich LM, Folsom AR, Key NS, Boland LL, Heckbert SR, Rosamond WD, et al. Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism. J Thromb Haemost 2006; 4 (9): Schulman S, Lindmarker P, Holmström M, Lärfars G, Carlsson A, Nicol P, et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4 (4): Squizzato A, Romualdi E, Ageno W. Why should statins prevent venous thromboembolism A systematic literature search and a call for action. J Thromb Haemost 2006; 4 (9): Lopez-Pedrera C, Ruiz-Limon P, Aguirre MA, Rodriguez-Ariza A, Cuadrado MJ. Potential use of statins in the treatment of antiphospholipid syndrome. Curr Rheumatol Rep 2012; 14(1): Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360 (18): Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000; 132 (9): Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161 (11): Lacuta K, Le Gala G, Abalainc J, et al. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thrombosis Research 2008; 122 (3): Doggen C, Lemaitre R, Smith N, et al. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004; 2 (5): Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG- CoA-reductase inhibitors, other lipid lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009; 7 (4): Sorensen H, Horvath-Puho E, Sogaard K, et al. Arterial cardiovascular events, statins, low dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 2009; 7 (4): Undas A, Brummel K, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor V a initiation. Circulation 2001; 103 (18): Khemasuwan D, Chae Y, Neagu S, et al. Statin use may reduce the occurrence of venous thromboembolism: a study in patients with atherosclerotic disease. CHEST 2009; 4: Khemasuwan D, Divietro ML, Tangdhanakanond K, Pomerantz SC, Eiger G. Statins decrease the incidence of venous thromboembolism: retrospective study in patients with solid organ tumor. Am J Med 2010; 123 (1): Doggen C, Smith N, Lemaitre R, et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24 (10): Rodriguez AL, Wojcik BM, Wrobleski SK, Myers DD Jr, Wakefield TW, Diaz JA. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 2012; 33(4): Poredos P, Jezovnik MK. Dyslipidemia, statins, and venous thromboembolism. Semin Thromb Hemost 2011; 37(8):
Annals of RSCB Vol. XVII, Issue 1/2012
CORRELATIONS BETWEEN ENDOTHELIAL DYSFUNCTION AND GLYCEMIA IN VENOUS THROMBOSIS PATHOGENESIS Codruţa Bădescu 1, Oana Bădulescu 2, Manuela Ciocoiu 2, Magda Bădescu 2, M. Costuleanu 2 1 DEPARTMENT OF INTERNAL
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationMabel Labrada, MD Miami VA Medical Center
Mabel Labrada, MD Miami VA Medical Center *1-Treatment for acute DVT with underlying malignancy is for 3 months. *2-Treatment of provoked acute proximal DVT can be stopped after 3months of treatment and
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationAnnals of RSCB Vol. XVI, Issue 1
THE STUDY OF PROTHROBOTIC STATE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASES Oana Bădulescu 1, Codruţa Bădescu 2, Manuela Ciocoiu 1, Magda Bădescu 1 1 DEPARTMENT OF PATHOPHYSIOLOGY;
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationVTE in Children: Practical Issues
VTE in Children: Practical Issues Wasil Jastaniah MBBS,FAAP,FRCPC Consultant Pediatric Hem/Onc/BMT May 2012 Top 10 Reasons Why Pediatric VTE is Different 1. Social, ethical, and legal implications. 2.
More informationPROGNOSIS AND SURVIVAL
CANCER ASSOCIATED THROMBOSIS PROGNOSIS AND SURVIVAL Since French internist Armand Trousseau reported the occurrence of mysterious thrombotic disorders in cancer patients in the mid-19th century, the link
More informationStatins Decrease the Occurrence of Venous Thromboembolism in Patients with Cancer
CLINICAL RESEARCH STUDY Statins Decrease the Occurrence of Venous Thromboembolism in Patients with Cancer Danai Khemasuwan, MD, Matthew L. DiVietro, DO, Kawin Tangdhanakanond, MD, Sherry C. Pomerantz,
More informationThrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI
Thrombophilia Diagnosis and Management Kevin P. Hubbard, DO, FACOI Clinical Professor of Medicine Kansas City University of Medicine and Biosciences-College of Osteopathic Medicine Kansas City, Missouri
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationIs there an association between atherosclerosis and chronic venous disease?
Is there an association between atherosclerosis and chronic venous disease? Karel Roztocil, IKEM, Praha Hungarian Society of Angiology and Vascular Surgery Congress, Szombathely 2017 Disclosure Nothing
More informationVenous thromboembolism and atherosclerosis: common denominators or different diseases?
Journal of Thrombosis and Haemostasis, 4: 1886 1890 COMMENTARY Venous thromboembolism and atherosclerosis: common denominators or different diseases? G. AGNELLI and C. BECATTINI Division of Internal and
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationApproach to Thrombosis
Approach to Thrombosis Theera Ruchutrakool, M.D. Division of Hematology Department of Medicine Siriraj Hospital Faculty of Medicine Mahidol University Approach to Thrombosis Thrombosis: thrombus formation
More informationEpidemiologia e clinica del tromboembolismo venoso. Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione
Epidemiologia e clinica del tromboembolismo venoso Maria Ciccone Sezione di Ematologia e Fisiopatologia della Coagulazione Thrombophilia may present clinically as one or more of several thrombotic manifestations
More informationThyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A.
UvA-DARE (Digital Academic Repository) Thyroid disease and haemostasis: a relationship with clinical implications? Squizzato, A. Link to publication Citation for published version (APA): Squizzato, A.
More informationHow long to continue anticoagulation after DVT?
How long to continue anticoagulation after DVT? Dr. Nihar Ranjan Pradhan M.S., DNB (Vascular Surgery), FVES(UK) Consultant Vascular Surgeon Apollo Hospital, Jubilee Hills, Hyderabad (Formerly Faculty in
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationUpdates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis. By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan
Updates in Medical Management of Pulmonary Embolism and Deep Vein Thrombosis By: Justin Youtsey, Elliott Reiff, William Montgomery, Grant Finlan Objectives Describe the prevalence of PE and DVT as it relates
More informationIs Oral Rivaroxaban Safe and Effective in the Treatment of Patients with Symptomatic DVT?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 1-1-2013 Is Oral Rivaroxaban Safe and Effective
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationVenous thrombosis is common and often occurs spontaneously, but it also frequently accompanies medical and surgical conditions, both in the community
Venous Thrombosis Venous Thrombosis It occurs mainly in the deep veins of the leg (deep vein thrombosis, DVT), from which parts of the clot frequently embolize to the lungs (pulmonary embolism, PE). Fewer
More informationWhat are blood clots?
What are blood clots? Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service GP Partner Westcliffe Medical Group Created 5/31/18 Dr. Matthew
More informationAre there still any valid indications for thrombophilia screening in DVT?
Carotid artery stenosis and risk of stroke Are there still any valid indications for thrombophilia screening in DVT? Armando Mansilha MD, PhD, FEBVS Faculty of Medicine of University of Porto Munich, 2016
More informationGenetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수
Genetic Tests for the Better Outcome of VTE? 서울대학교병원혈액종양내과윤성수 Thrombophilia A hereditary or acquired disorder predisposing to thrombosis Questions Why should we test? Who should we test For what disorders?
More informationChapter 1. Introduction
Chapter 1 Introduction Introduction 9 Even though the first reports on venous thromboembolism date back to the 13 th century and the mechanism of acute pulmonary embolism (PE) was unraveled almost 150
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/40114 holds various files of this Leiden University dissertation Author: Exter, Paul L. den Title: Diagnosis, management and prognosis of symptomatic and
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationSindrome da anticorpi antifosfolipidi: clinica e terapia. Vittorio Pengo Clinical Cardiology, Padova, Italy
Sindrome da anticorpi antifosfolipidi: clinica e terapia Vittorio Pengo Clinical Cardiology, Padova, Italy Revised Classification Criteria for the Antiphospholipid Syndrome J Thromb Haemost 2006;4:295-306
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC 1 st workshop: update to VTE guidelines in 2016 2 nd workshop: VTE controversies + new horizons André Roussin MD, FRCP, CSPQ CHUM
More informationResults from Hokusai-VTE presented during ESC Congress 2013 Hot Line session and published in the New England Journal of Medicine
Press Release Daiichi Sankyo s Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE
More informationPathology of pulmonary vascular disease. Dr.Ashraf Abdelfatah Deyab. Assistant Professor of Pathology Faculty of Medicine Almajma ah University
Pathology of pulmonary vascular disease Dr.Ashraf Abdelfatah Deyab Assistant Professor of Pathology Faculty of Medicine Almajma ah University Pulmonary vascular disease Type of pulmonary circulation: Types
More informationSlide 1. Slide 2. Slide 3. Outline of This Presentation
Slide 1 Current Approaches to Venous Thromboembolism Prevention in Orthopedic Patients Hujefa Vora, MD Maria Fox, RN June 9, 2017 Slide 2 Slide 3 Outline of This Presentation Pathophysiology of venous
More informationCHAPTER 2 VENOUS THROMBOEMBOLISM
CHAPTER 2 VENOUS THROMBOEMBOLISM Objectives Venous Thromboembolism (VTE) Prevalence Patho-physiology Risk Factors Diagnosis Pulmonary Embolism (PE) Management of DVT/PE Prevention VTE Patho-physiology
More informationJordan M. Garrison, MD FACS, FASMBS
Jordan M. Garrison, MD FACS, FASMBS Peripheral Arterial Disease (PAD) Near or Complete obstruction of > 1 Peripheral Artery Peripheral Venous reflux Disease Varicose Veins Chronic Venous Stasis Ulcer Disease
More informationLearning Objectives for Rotations in Vascular Surgery Year 3 Basic Clerkship
Learning Objectives for Rotations in Vascular Surgery Year 3 Basic Clerkship CLINICAL PROBLEMS IN VASCULAR SURGERY 1. ABDOMINAL AORTIC ANEURYSM A 70 year old man presents in the emergency department with
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationStatin treatment and the risk of recurrent pulmonary embolism
European Heart Journal (2013) 34, 1800 1806 doi:10.1093/eurheartj/eht046 CLINICAL RESEARCH Thrombosis and antithrombotic therapy Statin treatment and the risk of recurrent pulmonary embolism Sara Biere-Rafi
More informationRisk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationVenous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More informationMisunderstandings of Venous thromboembolism prophylaxis
Misunderstandings of Venous thromboembolism prophylaxis Veerendra Chadachan Senior Consultant Dept of General Medicine (Vascular Medicine and Hypertension) Tan Tock Seng Hospital, Singapore Case scenario
More informationHEART HEALTH WEEK 2 SUPPLEMENT. A Beginner s Guide to Cardiovascular Disease ATHEROSCLEROSIS. Fatty deposits can narrow and harden the artery
WEEK 2 SUPPLEMENT HEART HEALTH A Beginner s Guide to Cardiovascular Disease ATHEROSCLEROSIS FIGURE 1 Atherosclerosis is an inflammatory process where cholesterol is deposited in the wall of arteries and
More informationTHROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO
THROMBOPHILIA TESTING: PROS AND CONS SHANNON CARPENTER, MD MS CHILDREN S MERCY HOSPITAL KANSAS CITY, MO DISCLAIMER I m a pediatrician I will be discussing this issue primarily from a pediatric perspective
More informationCANCER ASSOCIATED THROMBOSIS. Pankaj Handa Department of General Medicine Tan Tock Seng Hospital
CANCER ASSOCIATED THROMBOSIS Pankaj Handa Department of General Medicine Tan Tock Seng Hospital My Talk Today 1.Introduction 2. Are All Cancer Patients at Risk of VTE? 3. Should All VTE Patients Be Screened
More informationHemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.
Hemodynamic Disorders, Thrombosis, and Shock Richard A. McPherson, M.D. Edema The accumulation of abnormal amounts of fluid in intercellular spaces of body cavities. Inflammation and release of mediators
More information10/24/2013. Heparin-Induced Thrombocytopenia (HIT) Anticoagulation Management in ECMO Therapy:
Anticoagulation Management in ECMO Therapy: Heparin-Induced (HIT) Michael H. Creer, MD Professor of Pathology Director, Clinical Laboratories, Medical Co- Director, Hematopathology and Chief, Division
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPE and DVT. Dr Anzo William Adiga WatsApp or Call Medical Officer/RHEMA MEDICAL GROUP
PE and DVT Dr Anzo William Adiga WatsApp or Call +256777363201 Medical Officer/RHEMA MEDICAL GROUP OBJECTIVES DEFINE DVT AND P.E PATHOPHYSIOLOGY OF DVT CLINICAL PRESENTATION OF DVT/PE INVESTIGATE DVT MANAGEMENT
More informationBacillopeptidase F Proprietary Blend (BFPB) A Natural Enzyme Extracted by a Patented Fermentation Production Process to Support Healthy Circulation
Bacillopeptidase F Proprietary Blend (BFPB) A Natural Enzyme Extracted by a Patented Fermentation Production Process to Support Healthy Circulation What is Plasmanex1? Plasmanex1 is a dietary supplement
More informationCausative factors of deep vein thrombosis of lower limb in Indian population
International Surgery Jthisnal Khadilkar R et al. Int Surg J. 18 Jan;(1):3-3 http://www.ijsurgery.com pissn 39-33 eissn 39-9 Original Research Article DOI: http://dx.doi.org/1.183/39-9.isj17919 Causative
More informationAtherosclerosis and venous thromboembolism similarities
Kardiologia Polska 2013; 71, 12: 1223 1228; DOI: 10.5603/KP.2013.0322 ISSN 0022 9032 ARTYKUŁ SPECJALNY / STATE-OF-THE-ART REVIEW Atherosclerosis and venous thromboembolism similarities Anetta Undas Institute
More informationLung diseases of Vascular Origin. By: Shefaa Qa qqa
Lung diseases of Vascular Origin By: Shefaa Qa qqa Pulmonary Hypertension Pulmonary hypertension is defined as a mean pulmonary artery pressure greater than or equal to 25 mm Hg at rest. Based on underlying
More informationTop Ten Reasons For Failure To Prevent Postoperative Thrombosis
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical
More informationThursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III
REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels
More informationClinical Policy: Dalteparin (Fragmin) Reference Number: ERX.SPA.207 Effective Date:
Clinical Policy: (Fragmin) Reference Number: ERX.SPA.207 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationHandbook for Venous Thromboembolism
Handbook for Venous Thromboembolism Gregory Piazza Benjamin Hohlfelder Samuel Z. Goldhaber Handbook for Venous Thromboembolism Gregory Piazza Cardiovascular Division Harvard Medical School Brigham and
More informationDr. Rami M. Adil Al-Hayali Assistant Professor in Medicine
Dr. Rami M. Adil Al-Hayali Assistant Professor in Medicine Venous thromboembolism: pulmonary embolism (PE) deep vein thrombosis (DVT) 1% of all patients admitted to hospital 5% of in-hospital mortality
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationAntiphospholipid Antibody Syndrome: Management Issues for the Hematologist
Antiphospholipid Antibody Syndrome: Management Issues for the Hematologist Wisconsin Institute of Discovery Karen Rossi/Bristol-Myers Squibb Morey A. Blinder, MD Washington University, St. Louis, MO March
More informationInherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD
Inherited Thrombophilia Testing George Rodgers, MD, PhD Kristi Smock MD Prevalence and risk associated with inherited thrombotic disorders Inherited Risk Factor % General Population % Patients w/ Thrombosis
More informationTHROMBOSIS. Dr. Nisreen Abu Shahin Assistant Professor of Pathology Pathology Department University of Jordan
THROMBOSIS Dr. Nisreen Abu Shahin Assistant Professor of Pathology Pathology Department University of Jordan NORMAL BLOOD VESSEL HISTOLOGY THROMBOSIS Pathogenesis (called Virchow's triad): 1. Endothelial*
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationThrombophilia: To test or not to test
Kenneth Bauer, MD Harvard Medical School, Boston, MA Professor of Medicine VA Boston Healthcare System Chief, Hematology Section Beth Israel Deaconess Medical Center, Boston, MA Director, Thrombosis Clinical
More informationBath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)
Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf
More informationVenous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital
Venous Thromboembolism Prophylaxis - Why Should We Care? Harry Gibbs FRACP FCSANZ Vascular Physician The Alfred Hospital VTE is common and dangerous 5 VTE is Common VTE Incidence: 1.5 / 1000 per year
More informationHow to prevent thrombotic diseases? Sergio Fusco, MD
How to prevent thrombotic diseases? Sergio Fusco, MD Geriatric Division - Department of Internal Medicine Ospedale Dell'Angelo - Venice, Italy CONFLICT OF INTEREST DISCLOSURE I have no potential conflict
More informationTHROMBOPHILIA SCREENING
THROMBOPHILIA SCREENING Introduction The regulation of haemostasis Normally, when a clot occurs, it exactly occurs where it has to be and does not grow more than necessary due to the action of the haemostasis
More informationCover Page. The following handle holds various files of this Leiden University dissertation:
Cover Page The following handle holds various files of this Leiden University dissertation: http://hdl.handle.net/1887/59465 Author: Morelli, V.M. Title: Cardiometabolic risk factors and venous thrombosis
More informationTHROMBOSIS RISK FACTOR ASSESSMENT
Name: Procedure: Doctor: Date: THROMBOSIS RISK FACTOR ASSESSMENT CHOOSE ALL THAT APPLY EACH RISK FACTOR REPRESENTS 1 POINT Age 41 60 years Minor Surgery Planned History of Prior Major Surgery (< 1 month)
More informationAnticoagulation in Special populations. Ng Heng Joo Department of Haematology Singapore General Hospital
Anticoagulation in Special populations Ng Heng Joo Department of Haematology Singapore General Hospital roymatheson.com Objectives Safer anticoagulation for The elderly Chronic kidney disease Obese patients
More informationThrombosis. By Dr. Sara Mohamed Abuelgasim
Thrombosis By Dr. Sara Mohamed Abuelgasim 1 Thrombosis Unchecked, blood coagulation would lead to dangerous occlusion of blood vessels if the protective mechanisms of coagulation factor inhibitors, blood
More informationPaolo Prandoni Università di Padova
Paolo Prandoni Università di Padova Il domani doloroso della TVP FCSA, Bologna 2014 Teatro Anatomico Università di Padova Eventi attesi a distanza da un evento tromboembolico venoso Recidiva di TEV PTS
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/19768 holds various files of this Leiden University dissertation. Author: Langevelde, Kirsten van Title: Are pulmonary embolism and deep-vein thrombosis
More informationHEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the investigation and management of suspected and documented heparin-induced thrombocytopenia (HIT). BACKGROUND: HIT is a transient,
More informationREVIEW ON PULMONARY EMBOLISM
REVIEW ON PULMONARY EMBOLISM * Shashi Kumar Yadav, Prof. Xiao Wei, Roshan Kumar Yadav, Sanjay Kumar Verma and Deepika Dhakal * Department of Medicine, Clinical College of Yangtze University, The first
More informationDr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital Foundation Trust
MANAGEMENT OF PATIENTS WITH DEEP VEIN THROMBOSIS (DVT) IN THE COMMUNITY SETTING & ANTICOAGULATION CLINICS THE PAST, PRESENT AND THE FUTURE Dr. Riaz JanMohamed Consultant Haematologist The Hillingdon Hospital
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationPULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT
PULMONARY EMBOLISM (PE): DIAGNOSIS AND TREATMENT OBJECTIVE: To provide a diagnostic algorithm and treatment options for patients with acute pulmonary embolism (PE). BACKGROUND: Venous thromboembolism (VTE)
More informationThis chapter will describe the effectiveness of antithrombotic
Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Harry R. Büller, MD, Chair; Giancarlo Agnelli, MD; Russel D. Hull, MBBS,
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationDr. Pierpaolo Di Micco Internal Medicine and Emergency Room Fatebenefratelli Hospital of Naples, Italy
? Para què sirve el recuento de leucocitos en lospacientescon cancer? Dr. Pierpaolo Di Micco Internal Medicine and Emergency Room Fatebenefratelli Hospital of Naples, Italy ? Para què sirve el recuento
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/21764 holds various files of this Leiden University dissertation. Author: Mos, Inge Christina Maria Title: A more granular view on pulmonary embolism Issue
More informationThrombosis and emboli. Peter Nagy
Thrombosis and emboli Peter Nagy A thrombus is any solid object developing from the blood in vivo within the vascular system or heart. Thrombosis is hemostasis in the wrong place. Major components, forms:
More informationHematologic Disorders. Assistant professor of anesthesia
Preoperative Evaluation Hematologic Disorders Dr M.Razavi Assistant professor of anesthesia Anemia Evaluation needs to consider the extent and type of surgery, the anticipated blood loss, and the patient's
More informationVenous Thromboembolism Prophylaxis
Approved by: Venous Thromboembolism Prophylaxis Vice President and Chief Medical Officer; and Vice President and Chief Operating Officer Corporate Policy & Procedures Manual Number: Date Approved January
More informationVenous Thromboembolism National Hospital Inpatient Quality Measures
Venous Thromboembolism National Hospital Inpatient Quality Measures Presentation Overview Review venous thromboembolism as a new mandatory measure set Outline measures with exclusions and documentation
More informationCADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm
CADTH Rapid Response Report: ASA for Venous Thromboembolism Prophylaxis: Evidence for Clinical Benefit and Harm P. Timothy Pollak, MD, PhD University of Calgary Rocky Mountain/ACP Internal Medicine Meeting,
More information